Chimeric antigen receptor T ( CAR‐T ) cells: Novel cell therapy for hematological malignancies
Cancer Medicine · 2023-04 · 12 (7) · 7844-7858
DOI: 10.1002/cam4.5551 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 30.12.2022. Verfasst von Samane Abbasi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms, Multiple Myeloma. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Over the last decade, the emergence of several novel therapeutic approaches has changed the therapeutic perspective of human malignancies. Adoptive immunotherapy through chimeric antigen receptor T cell (CAR‐T), which includes the engineering of T cells to recognize tumor‐specific membrane antigens and, as a result, death of cancer cells, has created various clinical benefits for the treatment of several human malignancies. In particular, CAR‐T‐cell‐based immunotherapy is known as a critical approach for the treatment of patients with hematological malignancies such as acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), and non‐Hodgkin's lymphoma (NHL). However, CAR‐T‐cell therapy of hematological malignancies is associated with various side effects. There are still extensive challenges in association with further progress of this therapeutic approach, from manufacturing and engineering issues to limitations of applications and serious toxicities. Therefore, further studies are required to enhance efficacy and minimize adverse events. In the current review, we summarize the development of CAR‐T‐cell‐based immunotherapy and current clinical antitumor applications to treat hematological malignancies. Furthermore, we will mention the current advantages, disadvantages, challenges, and therapeutic limitations of CAR‐T‐cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.
- Department of Clinical Immunology, Faculty of Medicine, The University of Manchester, Manchester, UK.
- Department of Microbiology, Malekan Branch, Islamic Azad University, Malekan, Iran.
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Genetics, Faculty of Biology, Sana Institute of Higher Education, Sari, Iran.
- Department of Genetics and Biotechnology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Alireza Isazadeh, Behzad Baradaran
Zitieren
APA
Abbasi, S., Totmaj, M. A., Abbasi, M., Hajazimian, S., Goleij, P., Behroozi, J., Shademan, B., Isazadeh, A., & Baradaran, B. (2023). Chimeric antigen receptor T ( CAR‐T ) cells: Novel cell therapy for hematological malignancies. Cancer Medicine, 12(7), 7844-7858. https://doi.org/10.1002/cam4.5551
Vancouver
Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. Chimeric antigen receptor T ( CAR‐T ) cells: Novel cell therapy for hematological malignancies. Cancer Medicine. 2023;12(7):7844-7858. doi:10.1002/cam4.5551
BibTeX
@article{Abbasi2023,
author = {Abbasi, Samane and Totmaj, Milad Asghari and Abbasi, Masoumeh and Hajazimian, Saba and Goleij, Pouya and Behroozi, Javad and Shademan, Behrouz and Isazadeh, Alireza and Baradaran, Behzad},
title = {Chimeric antigen receptor T ( CAR‐T ) cells: Novel cell therapy for hematological malignancies},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {7},
pages = {7844--7858},
doi = {10.1002/cam4.5551}
}
EUVIMED